Dr. Poizsolt Franz
My Social Links

Dr. Poizsolt Franz

President of Health Services Research
Institute of Clinical Economics e.V. - Startseite, Germany

Highest Degree
Ph.D. in Tumor Biology from University of Ulm, Germany

Share this Profile

Area of Interest:

Biomedical Sciences
100%
Biomolecular Research
62%
Internal Medicine
90%
Medical Oncology
75%
Hematology
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Silva-Sobrinho, R.A., A. Zilly and F. Porzsolt, 2018. Development of the nursing profession: From nursing angel to patient advocate. J. Nurs. Educ. Pract., 8: 16-22.
  2. Porzsolt, F. and K.W. Jauch, 2018. Variety and scientific value of randomized studies. Lack of real world effectiveness. Dtsch. Arztebl., 115: 214-215.
  3. Manzini, G., D. Henne-Bruns, F. Porzsolt and M. Kremer, 2017. Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? A comparison of eight guidelines. BMJ Open Gastroenterol., Vol. 4. 10.1136/bmjgast-2016-000129.
    CrossRef  |  Direct Link  |  
  4. Von Gottberg, C., S. Krumm, F. Porzsolt and R. Kilian, 2016. The analysis of factors affecting municipal employees’ willingness to report to work during an influenza pandemic by means of the extended parallel process model (EPPM). BMC Public Health, Vol. 16. 10.1186/s12889-015-2663-8.
    CrossRef  |  
  5. Rosati, P., F. Porzsolt, G. Ricciotti, G. Testa and R. Inglese et al., 2016. Major discrepancies between what clinical trial registries record and paediatric randomised controlled trials publish. Trials, Vol. 17. 10.1186/s13063-016-1551-6.
    CrossRef  |  
  6. Porzsolt, F., D. Ittner and D. Henne-Bruns, 2016. [Validity of recommendations for secondary prevention of colon cancer]. Tumor Diagnostik Therapie, 37: 195-201.
    CrossRef  |  Direct Link  |  
  7. Porzsolt, F., 2016. Clinical economics-it is about values not about money. Braz. J. Med. Human Health, 4: 82-88.
    CrossRef  |  Direct Link  |  
  8. Nampo, F.K., C. Weiss and F. Porzsolt, 2016. Comments on light-emitting diode therapy (LEDT) before matches prevents increase in creatine kinase with a light dose response in volleyball players. Lasers Med. Sci., 31: 1273-1274.
    CrossRef  |  
  9. Correia, L.C., A. Latado and F. Porzsolt, 2016. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med., 375: 1797-1799.
    CrossRef  |  
  10. Porzsolt, F., N.G. Rocha, A.C. Toledo-Arruda, T.G. Thomaz and C. Moraes et al., 2015. Efficacy and effectiveness trials have different goals, use different tools and generate different messages. Pragmatic Observ. Res., 6: 47-54.
    CrossRef  |  
  11. Porzsolt, F., 2015. Clinical economics and nursing. Revista Latino-Americana de Enfermagem, 23: 989-990.
    CrossRef  |  Direct Link  |  
  12. Bauer, K., M. Schroeder, F. Porzsolt and D. Henne-Bruns, 2015. Comparison of international guidelines on the accompaning therapies for gastric cancer. Reasons for the differences. J. Gastric Cancer, 15: 10-18.
  13. Wockel, A., W. Janni, F. Porzsolt and R. Schmutzler, 2014. Benefits and risks of breast cancer screening. Oncol. Res. Treat., 37: 21-28.
    CrossRef  |  
  14. Bauer, K., F. Porzsolt and D. Henne-Bruns, 2014. Can perioperative chemotherapy for advanced gastric cancer be recommended on the basis of current research? A critical analysis. J. Gastric Cancer, 14: 39-46.
  15. Weiss, M., F. Lautenschlager and F. Porzsolt, 2013. Surviving sepsis campaign bundles adherence and their limits in surgical patients with septic shock in an ICU. Br. J. Med. Med. Res., 3: 94-107.
  16. Rosati, P. and F. Porzsolt, 2013. A practical educational tool for teaching child-care hospital professionals attending evidence-based practice courses for continuing medical education to appraise internal validity in systematic reviews. J. Eval. Clin. Pract., 4: 648-652.
    CrossRef  |  
  17. Porzsolt, F., T.G. Thomaz, T.I. Constancio, A.G. da Silva-Junior and A.C.L. da Nobrega, 2013. The risks of information in health care: Do we need a new decision aid? Clinics, 68: 1177-1179.
    CrossRef  |  
  18. Porzsolt, F., M. Eisemann, M. Habs and P. Wyer, 2013. Form follows function: Pragmatic controlled trials (PCTs) have to answer different questions and require different designs than randomized controlled trials (RCTs). J. Public Health, 21: 307-313.
  19. Porzsolt, F., J. Bausch, G. Geipel, E. Huppertz and A. Muhlbacher et al., 2013. [Adequate evidence for treatment decisions: A discussion of the pluralism of methods in clinical trials]. Gesundh Okon Qual. Manage., 18: 31-39.
    CrossRef  |  Direct Link  |  
  20. Porzsolt, F., 2013. Balancing conflicts of interest (related to guidelines). Dtsch. Arztebl. Int., 110: 286-288.
  21. Bauer, K., F. Porzsolt and D. Henne-Bruns, 2013. Validity of the magic study: Sufficient for recommendations? Hepatogastroenterology, 60: 1822-1824.
  22. Weiss, M., F. Grom and F. Porzsolt, 2012. Costs of additional treatment success (COATS) based on numbers needed to treat (NNT) is a simplified calculation method to facilitate physicians medical decisions with regards to monetary costs. Br. J. Med. Med. Res., 2: 636-642.
  23. Porzsolt, F., U. Bittner and J. Clouth, 2012. Scientists and clinicians have to be on the qui VIVE: Benefit, outcome, value and utility in health care as a challenge. J. Public Health, 20: 479-482.
    CrossRef  |  
  24. Porzsolt, F., P. Braubach, P.I. Flurschutz, A. Goller, M.B. Sailer, M. Weiss and P. Wyer, 2012. Medical students help avoid the expert bias in medicine. Creative Educ., 3: 1115-1121.
    CrossRef  |  
  25. Porzsolt, F., P. Braubach, E. Huppertz, A. Muhlbacher and T. Otto et al., 2012. Benefit assessment of pharmaceutical products. Gesundh Okon Qual. Manage., 17: 283-290.
  26. Kornmann, M., S. Hofmann, J. Vetter, C. Wachter, D. Henne-Bruns and F. Porzsolt, 2012. Visual aids for multimodal treatment options to support decision making of patients with colorectal cancer. BMC Med. Inform. Decision Making, Vol. 12. 10.1186/1472-6747-12-118.
    CrossRef  |  
  27. Porzsolt, F., I. Polianski, A. Gorgen and M. Eisemann, 2011. Safety and security: The valences of values. J. Applied Security Res., 6: 483-490.
    CrossRef  |  
  28. Porzsolt, F., H. Fink and B. Bert, 2011.. Controlled but pragmatic investigations of interventions for behavioural disturbances in dogs and cats. Berl. Munch Tierarztl. Wochenschr., 124: 10-13.
    CrossRef  |  
  29. Coppin, C., C. Kollmannsberger, L. Le, F. Porzsolt and T.J. Wilt, 2011. Targeted therapy for advanced renal cell cancer (RCC): A Cochrane systematic review of published randomised trials. BJU Int., 108: 1556-1563.
    CrossRef  |  Direct Link  |  
  30. Porzsolt, F., M. Eisemann and M. Habs, 2010. Complementary alternative medicine and conventional medicine should use identical rules to complete clinical trials. Eur. J. Integr. Med., 2: 3-7.
    CrossRef  |  Direct Link  |  
  31. Porzsolt, F., J. Clouth, M. Deutschmann and H.J. Hippler, 2010. Preferences of diabetes patients and physicians: A feasibility study to identify the key indicators for appraisal of health care values. Health Qual. Life Outcomes, Vol. 8. 10.1186/1477-7525-8-125.
    CrossRef  |  
  32. Porzsolt, F., H. Pressel, C. Maute-Stephan, R. Kindervater and J. Geldmacher et al., 2010. Appraisal of healthcare: From patient value to societal benefit. J. Public Health, 18: 297-302.
    CrossRef  |  
  33. Porzsolt, F., 2010. The Y-nurse-pain in the neck or blessing for the team. BMJ Blog. .
    Direct Link  |  
  34. Porzsolt, F., 2010. Priority setting in health care systems: Too much or not enough. J. Public Health, 18: 95-96.
    CrossRef  |  
  35. Porzsolt, F., 2010. Implementing economic principles in medicine while maintaining medical professionalism. J. Public Health, 18: 199-203.
    CrossRef  |  
  36. Koensgen, D., G. Oskay-Oezcelik, I. Katsares, U. Walle and C. Klapp et al., 2010. Development of the Berlin symptom checklist ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: Results of a phase I and II study. Supportive Care Cancer, 18: 931-942.
    CrossRef  |  Direct Link  |  
  37. Porzsolt, F., I.C.B.O. Costa, T.G. Thomaz and for the SHUFFLE Group, 2009. Advantages and limitations of twin assessment of clinical trials (TACT). J. Public Health, 17: 425-435.
    CrossRef  |  
  38. Porzsolt, F., A. Kirner and R.M. Kaplan, 2009. Predictors of successful cancer prevention programs. Recent Results Cancer Res., 181: 19-31.
  39. Porzsolt, F. and D. Holzel, 2009. Spontaneous remissions in breast cancer underline the need of more evidence: Screening should not detect more cancer but earlier cancer. J. Public Health, 18: 15-19.
    CrossRef  |  
  40. Porzsolt, F., A.K. Ghosh and R.M. Kaplan, 2009. Qualitative assessment of innovations in healthcare provision. BMC Health Serv. Res., Vol. 9. 10.1186/1472-6963-9-50.
    CrossRef  |  Direct Link  |  
  41. Porzsolt, F., 2008. [Hidden jewels of disease management programs]. Gesundh Okon Qual. Manage, 4: 234-240.
    CrossRef  |  Direct Link  |  
  42. Kornmann, M. and F. Porzsolt, 2008. Treatment preferences of physicians and lay persons: Lessons from a study analysing neoadjuvant treatment of rectal carcinoma. J. Clin. Oncol., 26: 2866-4868.
  43. Kaplan, R.M. and F. Porzsolt, 2008. The natural history of breast cancer. Arch. Int. Med., 168: 2302-2303.
  44. Porzsolt, F., M. Ackermann and V. Amelung, 2007. The value of health care-a matter of discussion in Germany. BMC Health Serv. Res., Vol. 7. 10.1186/1472-6963-7-1.
    CrossRef  |  Direct Link  |  
  45. Nabulsi, M., J. Harris, L. Letelier, K. Ramos and K. Hopayian et al., 2007. Effectiveness of education in evidence‐based healthcare: The current state of outcome assessments and a framework for future evaluations. Int. J. Evid.‐Based Healthcare, 5: 468-476.
    CrossRef  |  Direct Link  |  
  46. Porzsolt, F., 2006. Significance of outcomes research for health insurance. Versicherungsmedizin., 58: 138-142.
  47. Porzsolt, F. and R. Kilian, 2006. [Clinical research, outcomes research, health care research]. Gesundh Okon Qual. Manage, 11: 311-318.
    CrossRef  |  Direct Link  |  
  48. Gehr, B.T., C. Weiss and F. Porzsolt, 2006. The fading of reported effectiveness. A meta-analysis of randomised controlled trials. BMC Med. Res. Methodol., Vol. 6. 10.1186/1471-2288-6-25.
    CrossRef  |  Direct Link  |  
  49. Stengel, D., K. Bauwens, J. Sehouli, G. Rademacher, S. Mutze, A. Ekkernkamp and F. Porzsolt, 2005. Emergency ultrasound-based algorithms for diagnosing blunt abdominal trauma. Cochrane Database Syst. Rev., Vol. 2. 10.1002/14651858.CD004446.pub2.
    CrossRef  |  Direct Link  |  
  50. Porzsolt, F., H. Kajnar, A. Awa, M. Fassler and B. Herzberger, 2005. Validity of original studies in health technology assessment reports: Significance of standardized assessment and reporting. Int. J. Technol. Assess. Health Care, 21: 410-413.
    CrossRef  |  Direct Link  |  
  51. Kilian, R. and F. Porzsolt, 2005. When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of the literature. Breast, 14: 636-642.
  52. Dawes, M., W. Summerskill, P. Glasziou, A. Cartabellotta and J. Martin et al., 2005. Sicily statement on evidence-based practice. BMC Med. Educ., Vol. 5. 10.1186/1472-6920-5-1.
    CrossRef  |  Direct Link  |  
  53. Porzsolt, F., N. Scholtz-Gorton, N. Biller-Andorno, A. Thim and K. Meissner et al., 2004. Applying evidence to support ethical decisions: Is the placebo really powerless? Sci. Eng. Ethics, 10: 119-132.
    CrossRef  |  Direct Link  |  
  54. Porzsolt, F., M. Kojer, M. Schmidl, E.R. Greimel, J. Sigle, J. Richter and M. Eisemann, 2004. A new instrument to describe indicators of well-being in old-old patients with severe dementia-the Vienna list. Health Qual. Life Outcomes, Vol. 2. 10.1186/1477-7525-2-10.
    CrossRef  |  Direct Link  |  
  55. Coppin, C., F. Porzsolt, M. Autenrieth, J. Kumpf, A. Coldman and T. Wilt, 2004. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev., Vol. 2004. 10.1002/14651858.CD001425.pub2.
    CrossRef  |  Direct Link  |  
  56. Stengel, D., K. Bauwens, J. Sehouli, A. Ekkernkamp and F. Porzsolt, 2003. A likelihood ratio approach to meta-analysis of diagnostic studies. J. Med. Screening, 10: 47-51.
  57. Stengel, D., K. Bauwens, F. Porzsolt, G. Rademacher, S. Mutze and A. Ekkernkamp, 2003. [Emergency ultrasound for blunt abdominal trauma-meta-analysis update 2003]. Zentralblatt fur Chirurgie, 128: 1027-1037.
    CrossRef  |  Direct Link  |  
  58. Schrader, P., H.P. Scharf, K.P. Gunther, W. Puhl and F. Porzsolt, 2003. Evidence-based medicine in orthopedics-a sensible or unnecessary addition to clinical routine? Part 1: The diagnostics tool. Zeitschrift fur Orthopadie und ihre Grenzgebiete, 141: 386-390.
    PubMed  |  
  59. Schrader, P., H.P. Scharf, K.P. Gunther, W. Puhl and F. Porzsolt, 2003. Evidence-based medicine in orthopaedics-a sensible or unnecessary addition to clinical routine? Part 2: The therapy tool. Zeitschrift fur Orthopadie und ihre Grenzgebiete, 141: 391-394.
    PubMed  |  
  60. Porzsolt, F., A. Ohletz, A. Thim, D. Gardner and H. Ruatti et al., 2003. Evidence-based decision making-The six step approach. BMJ Evid.-Based Med., 8: 165-166.
    CrossRef  |  Direct Link  |  
  61. Stengel, D., K. Bauwens, J. Sehouli, F. Porzsolt, G. Rademacher, S. Mutze and A. Ekkernkamp, 2001. Systematic review and meta‐analysis of emergency ultrasonography for blunt abdominal trauma. Br. J. Surg., 88: 901-912.
    CrossRef  |  Direct Link  |  
  62. Stengel, D., K. Bauwens, J. Sehouli, A. Ekkernkamp and F. Porzsolt, 2001. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect. Dis., 1: 175-188.
    CrossRef  |  Direct Link  |  
  63. Porzsolt, F., S. Gottler, H. Leonhardt-Huober, A. Ohletz and C. Sellenthin et al., 2001. Evidence-based Medicine in internal medicine. Terminology, goal, programme, implementation and perspectives. Internistische Praxis, 41: 463-473.
  64. Porzsolt, F., H. Leonhardt-Huober and R. Stephens, 2001. Systematic review of the relationship between quality of life and survival in cancer patients. Breast, 10: 171-181.
    CrossRef  |  Direct Link  |  
  65. Frosch, D., F. Porzsolt, R. Heicappell, K. Kleinschmidt, M. Schatz, S. Weinknecht and R.M. Kaplan, 2001. Comparison of German language versions of the QWB-SA and SF-36 evaluating outcomes for patients with prostate disease. Qual. Life Res., 10: 165-173.
    CrossRef  |  Direct Link  |  
  66. Konig, E.A., W.C. Kusser, C. Day, F. Porzsolt and B.W. Glickman et al., 2000. p53 mutations in hairy cell leukemia. Leukemia, 14: 706-711.
    CrossRef  |  Direct Link  |  
  67. Eisemann, M., J. Richter, B. Bauer, R. Bonelli and F. Porzsolt, 1999. Physicians' decision-making in incompetent elderly patients: A comparative study between Austria, Germany (East, West) and Sweden. Int. Psychogeriatr., 11: 313-324.
    CrossRef  |  Direct Link  |  
  68. Sigle, J.M. and F. Porzsolt, 1998. High-dose chemotherapy in solid tumors. Point of patient advovacy view. Oncol. Nurses Today, 3: 14-15.
  69. Rothenbacher, D., M.P. Lutz and F. Porzsolt, 1997. Treatment decisions in palliative cancer care: Patients' preferences for involvement and doctors' knowledge about it. Eur. J. Cancer, 33: 1184-1189.
    CrossRef  |  Direct Link  |  
  70. Porzsolt, F. and R. Kunz, 1997. [Differences between evidence-based medicine and conventional, best medicine]. Med. Klin., 92: 567-569.
    CrossRef  |  Direct Link  |  
  71. Porzsolt, F. and R. Kunz, 1997. Evidence-based medicine. Langenbeck´s Arch. Chir., 2: 613-616.
  72. Demeter, J., F. Porzsolt, S. Ramisch, M. Schmid and G. Messer, 1997. Polymorphism of the tumour necrosis factor‐alpha and lymphotoxin‐alpha genes in hairy cell leukaemia. Br. J. Haematol., 97: 132-134.
    CrossRef  |  Direct Link  |  
  73. Demeter, J., F. Porzsolt, S. Ramisch, D. Schmidt, M. Schmid and G. Messer, 1997. Polymorphism of the tumour necrosis factor‐alpha and lymphotoxin‐alpha genes in chronic lymphocytic leukaemia. Br. J. Haematol., 97: 107-112.
    CrossRef  |  Direct Link  |  
  74. Coates, A., F. Porzsolt and D. Osoba, 1997. Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur. J. Cancer, 33: 1025-1030.
    CrossRef  |  Direct Link  |  
  75. Sigle, J. and F. Porzsolt, 1996. Practical aspects of quality-of-life measurement: Design and feasibility study of the quality-of-life recorder and the standardized measurement of quality of life in an outpatient clinic. Cancer Treat. Rev., 22: 75-89.
    Direct Link  |  
  76. Prummer, O., D. Bunjes, M. Wiesneth, B. Hertenstein, R. Arnold, F. Porzsolt and H. Heimpel, 1996. Antibodies to interferon-a: A novel type of autoantibodies occuring after bone marrow transplantation. Bone Marrow Transplantation, 17: 617-623.
  77. Porzsolt, F., C.P. Wolpl, C.E. Rist, R. Kosa, G. Buchele and W. Gaus, 1996. Comparison of three instruments (QLQ‐C30, SF‐36, QWB‐7) measuring health‐related quality of life/quality of well‐being. Psycho‐Oncol., 5: 103-117.
    CrossRef  |  Direct Link  |  
  78. Porzsolt, F., A. Wirth, R. Mayer-Steinacker, M. Schulte and G. Negri et al., 1996. Quality assurance by specification and achievement of goals in palliative cancer treatment. Cancer Treat. Rev., 22: 41-49.
    CrossRef  |  Direct Link  |  
  79. Demeter, J., G. Messer, S. Ramisch, J.B. Mee, M. Schmid, F. Herrmann and F. Porzsolt, 1996. Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol. Therapy, 2: 239-242.
    PubMed  |  
  80. Schmid, M., H. Schrezenmeier, G. Staib and F. Porzsolt, 1995. Evidence for a paracrine pathway of B‐cell stimulation in hairy cell leukaemia. Br. J. Haematol., 90: 156-162.
    CrossRef  |  Direct Link  |  
  81. Schmid, M. and F. Porzsolt, 1995. Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Leukemia Lymphoma, 17: 401-410.
    CrossRef  |  Direct Link  |  
  82. Porzsolt, F., R. Mayer-Steinacker and C. Eggl, 1995. Effectiveness and utility of a second-line treatment in metastatic breast cancer. Oncol. Res. Treat., 18: 48-52.
    CrossRef  |  Direct Link  |  
  83. Porzsolt, F., J. Zeeh and D. Platt, 1995. Palliative therapies in elderly cancer patients. Drugs Aging, 6: 192-209.
    CrossRef  |  Direct Link  |  
  84. Kranich, A.L., G. Gastl, E. Druckrey and F. Porzsolt, 1995. Symposium on health economics in oncology. J. Cancer Res. Clin. Oncol., 121: 691-693.
    CrossRef  |  Direct Link  |  
  85. Demeter, J., M. Schmid, P. Vargha and F. Porzsolt, 1995. Correlation of elevated plasma soluble IL-2 receptor levels with defective NK and CD8+ T-cells in myelodysplastic syndromes: Is it part of a spectrum? Leukemia Res., 19: 583-584.
  86. Demeter, J., M. Schmid and F. Porzsolt, 1995. Observations regarding hairy cell leukemia and chronic lymphocytic leukemia within the proposed new classification of lymphoid neoplasms. Blood, 85: 1972-1974.
    Direct Link  |  
  87. Spath-Schwalbe, E., J. Born, H. Schrezenmeier, S.R. Bornstein and P. Stromeyer et al., 1994. Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J. Clin. Endocrinol. Metab., 79: 1212-1214.
    CrossRef  |  Direct Link  |  
  88. Schmid, M., B. Merk and F. Porzsolt, 1994. Cyclosporin A inhibits cytokine-induced proliferation in B-chronic lymphocytic leukemia. Leukemia Lymphoma, 15: 317-325.
    CrossRef  |  Direct Link  |  
  89. Prummer, O., U. Streichan, H. Heimpel and F. Porzsolt, 1994. Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-α and IFN-β antibodies. J. Immunol. Methods, 171: 45-53.
    CrossRef  |  Direct Link  |  
  90. Prummer, O., D. Bunjes, M. Wiesneth, R. Arnold, F. Porzsolt and H. Heimpel, 1994. High-titre interferon-alpha antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transpl., 14: 483-486.
    Direct Link  |  
  91. Prummer, O. and F. Porzsolt, 1994. Recombinant IFN-a2 antibodies in renal cell carcinoma. J. Interferon Res., 14: 193-195.
  92. Porzsolt, F., M. Schmid, G. Staib and H. Schrezenmeier, 1994. Paracrine regulation of B-cell growth in hairy cell leukemia. Leukemia Lymphoma, 14: 13-18.
    Direct Link  |  
  93. Porzsolt, F., M. Schmid, D. Hoher, R. Muche, W. Gaus and M. Montenarh, 1994. Biologic relevance of auto-anti bodies against p53 in patients with metastatic breast cancer. Oncol. Res. Treat., 17: 402-408.
    CrossRef  |  Direct Link  |  
  94. Porzsolt, F., A. Wirth, R. Mayer-Steinacker, P. Suhr and N. Warszawski et al., 1994. Quality assurance in oncology: Definition of treatment goal and assessment of its achievement. Oncol. Res. Treat., 17: 454-457.
    CrossRef  |  Direct Link  |  
  95. Porzsolt, F., A. Wirth, R. Mayer-Steinacker, P. Suhr and N. Warszawski et al., 1994. Quality assurance in oncology: Definition of treatment goal and assessment of its achievement. Oncol. Res. Treat., 17: 454-457.
    CrossRef  |  Direct Link  |  
  96. Funke, I., E. Spath-Schwalbe, G. Stohlmann, O. Prummer, H. Gallati, H. Schrezenmeier and F. Porzsolt, 1994. Subcutaneous IL-2 and low-dose IFN-α2a in the treatment of unselected patients with advanced renal cell cancer. Oncol. Res. Treat., 17: 263-269.
    CrossRef  |  Direct Link  |  
  97. Demeter, J., P. Turbucz, D. Lehoczky and F. Porzsolt, 1994. Considerations on the pathogenesis of acute myeloid leukaemia in a splenectomized hairy cell leukaemia patient treated with Inteferon‐alpha. Br. J. Haematol., 86: 236-236.
    CrossRef  |  Direct Link  |  
  98. Demeter, J., H.J. Grote, C. Horvath, W.D. Gassel, G. Delling, J.M. Friedrich and F. Porzsolt, 1994. Bone densitometry and histomorphometry in patients with hairy cell leukemia. Leukemia Lymphoma, 13: 124-129.
  99. Prummer, O., 1993. Interferon‐alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon‐alpha‐2A in an adjuvant multicenter trial. Cancer, 71: 1828-1834.
    CrossRef  |  Direct Link  |  
  100. Porzsolt, F., 1993. Goals of palliative cancer therapy: Scope of the problem. Cancer Treat. Rev., 19: 3-14.
    CrossRef  |  Direct Link  |  
  101. Porzsolt, F. and N. MacDonald, 1993. Palliation in cancer patients. J. Cancer Res. Clin. Oncol., 119: 504-505.
    CrossRef  |  Direct Link  |  
  102. Porzsolt, F. and I. Tannock, 1993. Goals of palliative cancer therapy. J. Clin. Oncol., 11: 378-381.
    CrossRef  |  Direct Link  |  
  103. Hoher, D., S. Kartarius, F. Porzsolt and M. Montenarh, 1993. Immunologically defined subclasses of the growth suppressor protein p53 detected with antibodies in sera from tumor patients. Int. J. Oncol., 3: 741-747.
    CrossRef  |  Direct Link  |  
  104. Zillikens, D., M. Schuessler, R. Dummer, F. Porzsolt, A.A. Hartmann and G. Burg, 1992. Tumour necrosis factor in blister fluids of bullous pemphigoid. Eur. J. Dermatol., 2: 429-431.
    Direct Link  |  
  105. Porzsolt, E. and G. Meuret, 1992. Is non-symptomatic stable disease a relevant goal for treatment of metastatic breast cancer? Oncol. Res. Treat., 15: 25-30.
    CrossRef  |  Direct Link  |  
  106. Kern, P., C.J. Hemmer, H. Gallati, S. Neifer, P. Kremsner, M. Dietrich and F. Porzsolt, 1992. Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J. Infect. Dis., 166: 930-934.
    CrossRef  |  Direct Link  |  
  107. Digel, W., F. Porzsolt, M. Schmid, F. Herrmann, W. Lesslauer and M. Brockhaus, 1992. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J. Clin. Invest., 89: 1690-1693.
    CrossRef  |  
  108. Demeter, J. and F. Porzsolt, 1992. The clinical evaluation of hairy cell leukemia. Blood, 79: 2171-2173.
    Direct Link  |  
  109. Prummer, O., N. Frickhofen, W. Digel, H. Heimpel and F. Porzsolt, 1991. Spontaneous interferon-α antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann. Hematol., 62: 76-80.
    CrossRef  |  Direct Link  |  
  110. Prummer, O., N. Frickhofen, W. Digel, H. Heimpel and F. Porzsolt, 1991. Spontaneous interferon-α antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann. Hematol., 62: 76-80.
    CrossRef  |  Direct Link  |  
  111. Porzsolt, F., J. Demeter and H. Heimpel, 1991. Functional criteria for staging and treatment of hairy cell leukemia. Oncol. Res. Treat., 14: 44-48.
    CrossRef  |  Direct Link  |  
  112. Porzsolt, F. and G. Meuret, 1991. The kinetics of response are different in high-risk and low-risk patients with metastatic breast cancer. Oncol. Res. Treat., 14: 428-432.
    CrossRef  |  Direct Link  |  
  113. Porzsolt, F. and G. Meuret, 1991. Response rates and toxicity of mitomycin-C, Mitoxantrone and Methotrexate (3M) in advanced breast cancer. Oncol. Res. Treat., 14: 338-340.
    CrossRef  |  Direct Link  |  
  114. Digel, W., M. Schmid, G. Heil, P. Conrad, S. Gillis and F. Porzsolt, 1991. Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood, 78: 753-759.
    Direct Link  |  
  115. Digel, W., G. Zahn, G. Heinzel and F. Porzsolt, 1991. Pharmacokinetics and biological activity in subcutaneous long-term administration of recombinant interferon-γ in cancer patients. Cancer Immunol. Immunotherapy, 34: 169-174.
    CrossRef  |  Direct Link  |  
  116. Prummer, O., B. Cederblad, G. Alm, N. Drees and F. Porzsolt, 1990. Filter spot-ELISA for the enumeration of interferon-α antibody-secreting cells. J. Immunol. Methods, 130: 187-193.
    CrossRef  |  Direct Link  |  
  117. Porzsolt, F., E.D. Kreuser, G. Meuret, S. Mende and L. Buchelt et al., 1990. High-intensity therapy versus low-intensity therapy in advanced breast cancer patients. Cancer Treatment Rev., 17: 287-292.
    CrossRef  |  Direct Link  |  
  118. Porzsolt, F. and J. Demeter, 1990. When should hairy cell leukaemia be treated? Lancet, 336: 1387-1388.
  119. Digel, W., W. Schoniger, M. Stefanic, H. Janssen and C. Buck et al., 1990. Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood, 76: 1607-1613.
    Direct Link  |  
  120. Buck, C., W. Digel, W. Schoniger, M. Stefanic, A. Raghavachar, H. Heimpel and F. Porzsolt, 1990. Tumor necrosis factor O (TNF-O) but not lymphotoxin (LT) stimulates growth of cells in Hairy Cell Leukemia (HCL). Leukemia, 4: 431-434.
  121. Spath-Schwalbe, E., F. Porzsolt, W. Digel, J. Born, B. Kloos and H.L. Fehm, 1989. Elevated plasmacortisol levels during interferon-o-treatment. Immunopharmacology, 17: 141-145.
  122. Prummer, O., C. Seyfarth, W.A. Scherbaum, N. Drees and F. Porzsolt, 1989. Interferon-o antibodies in autoimmune diseases. J. Interferon Res., 9: 67-74.
  123. Prummer, O., C. Seyfarth, W.A. Scherbaum, N. Drees and F. Porzsolt, 1989. Interferon-alpha antibodies in autoimmune diseases. J. Interferon Res., 9: 67-74.
  124. Porzsolt, F., G. Meuret, E.D. Kreuser, S. Mende and L. Buchelt et al., 1989. Compliance of physicians and patients with a consensus protocol for treatment of advanced breast cancer. J. Cancer Res. Clin. Oncol., 115: 564-570.
    CrossRef  |  Direct Link  |  
  125. Porzsolt, F., A.M. Otto, B. Trauschel, C. Buck, A.W. Wawer and H. Schonenberger, 1989. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. J. Cancer Res. Clin. Oncol., 115: 465-469.
    CrossRef  |  Direct Link  |  
  126. Digel, W., M. Stefanic, W. Schoniger, C. Buck and A. Raghavachar et al., 1989. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood, 73: 1242-1246.
    Direct Link  |  
  127. Born, J., E. Spath-Schwalbe, R. Pietrowsky, F. Porzsolt and H.L. Fehm, 1989. Neurophysiological effects of recombinant interferon-gamma and-alpha in man. Clin. Physiol. Biochem., 7: 119-127.
    Direct Link  |  
  128. Anger, B., F. Porzsolt, R. Leichtle, B. Heinze, C. Bartram and H. Heimpel, 1989. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut, 58: 275-278.
    CrossRef  |  Direct Link  |  
  129. Raghavachar, A., N. Frickhofen, W. Digel, F. Porzsolt and H. Heimpel, 1988. Lymphokines as inhibitors of hematopoietic cell proliferation. Blood Cells, 14: 471-484.
    Direct Link  |  
  130. Porzsolt, F., W. Digel, H. Jacobsen, S. Mittnacht, H. Kirchner and H. Heimpel, 1988. Different antitumor mechanisms of interferon‐alpha in the treatment of hairy cell leukemia and renal cell cancer. Cancer, 61: 288-293.
    CrossRef  |  Direct Link  |  
  131. Porzsolt, F., D. Messerer, R. Hautmann, A. Gottwald and H. Sparwasser et al., 1988. Combination therapy of low dose alpha-interferon and medroxyprogesterone acetate in metastatic renal cell cancer. A randomized multicenter trial. J. Cancer Res. Clin. Oncol., 114: 95-100.
  132. Buck, C., W. Digel, W. Schoniger, M. Stefanic, A. Raghavachar and F. Porzsolt, 1988. Tumor necrosis factor and hairy cell leukemia. Lancet, 2: 402-403.
  133. Porzsolt, F., A. Raghavachar, W. Digel, C.R. Bartram and H. Heimpel, 1987. Strategy for the treatment of hairy cell leukemia. Leukemia, 1: 334-337.
    Direct Link  |  
  134. Ho, A.D., R. Kuse, O. Prummer, F. Porzsolt and W. Hunstein, 1987. 2'-Deoxycoformycin (Pentostatin) in hairy cell leukemia: Response in patients refractory to interferon alpha. Klinische Wochenschrift, 65: 975-979.
    CrossRef  |  Direct Link  |  
  135. Doney, K., R. Storb, C.D. Buckner, R. McGuffin and R. Witherspoon et al., 1987. Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids and androgens. Exp. Hematol., 15: 239-242.
    Direct Link  |  
  136. Bunjes, D., W. Heit, R. Arnold, T. Schmeiser and M. Wiesneth et al., 1987. Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow grafts. Transplantation, 43: 501-505.
    Direct Link  |  
  137. Seifried, E., G. Pindur, H. Stotter, F. Porzsolt and H. Rasche et al., 1986. HTLV III antibodies and immunological alterations in hemophilia patients. Klinische Wochenschrift, 64: 115-124.
    CrossRef  |  Direct Link  |  
  138. Raghavachar, A., N. Frickhofen, R. Arnold, T. Schmeiser, F. Porzsolt and H. Heimpel, 1986. Hematopoietic colony formation after allogeneic bone marrow transplantation: Enhancement by cyclosporin A and anti-gamma-(immune) interferon antiserum in vitro. Exp. Hematol., 14: 621-625.
    Direct Link  |  
  139. Porzsolt, F., R. Janik, G. Heil, O. Brudler and A. Raghavachar et al., 1986. Deficient IFNα production in hairy cell leukemia. Blut, 52: 185-190.
    CrossRef  |  Direct Link  |  
  140. Porzsolt, F., 1986. Report of the second international conference on hairy cell leukemia. Blut, 53: 443-445.
    CrossRef  |  Direct Link  |  
  141. Porzsolt, F., 1986. Primary treatment of hairy cell leukemia: Should IFN-therapy replace splenectomy? Blut, 52: 265-272.
    CrossRef  |  Direct Link  |  
  142. Frickhofen, N., W. Heit, A. Raghavachar, F. Porzsolt and H. Heimpel, 1986. Treatment of aplastic anemia with cyclosporin A, methylprednisolone and antithymocyte globulin. Klinische Wochenschrift, 64: 1165-1170.
    CrossRef  |  Direct Link  |  
  143. Porzsolt, F., J. Thoma, M. Unsold, W. Wolf, H.J. Obert, B. Kubanek and H. Heimpel, 1985. Platelet-adjusted IFN dosage in the treatment of advanced hairy cell leukemia. Blut, 51: 73-82.
    CrossRef  |  Direct Link  |  
  144. Porzsolt, F., M. Hauser, C. Piper, S. Scholz and H. Stotter et al., 1984. Impaired natural killer cell function in hemophiliacs with or without continuous substitution. Blut, 49: 61-65.
    CrossRef  |  Direct Link  |  
  145. Porzsolt, F., G. Groger, W. Vogel and H. Heimpel, 1984. Variations in the susceptibility to lysis of NK target cells. Oncology, 41: 270-275.
    CrossRef  |  Direct Link  |  
  146. Porzsolt, F. and H. Heimpel, 1984. The relationship of lytic effects against autologous and allogeneic PHA blasts induced in human mixed lymphocyte cultures. Immunol. Lett., 8: 33-38.
    CrossRef  |  Direct Link  |  
  147. Porzsolt, F., W. Gaus and H. Heimpel, 1983. The evaluation of serial measurements of the NK cell activity in man. Immunobiology, 165: 475-484.
    CrossRef  |  Direct Link  |  
  148. Porzsolt, F., 1983. Impaired natural killer cell function in preleukemia. Blood, 62: 1150-1150.
  149. Porzsolt, F. and W. Wolf, 1983. Modulation of natural killer activity by aspirin: I. In vitro effect of aspirin. J. Interferon Res., 3: 11-17.
    CrossRef  |  
  150. Porzsolt, F. and H. Heimpel, 1982. Impaired T-cell and NK-cell function in patients with preleukemia. Blut, 45: 243-248.
    CrossRef  |  Direct Link  |  
  151. Ganser, A., P. Nobis and F. Porzsolt, 1982. Modern trends in human leukemia. Blut, 45: 351-357.
  152. Porzsolt, F., 1981. The biology of the interferon system. Blut, 43: 325-328.
  153. Grohmann, P.H., F. Porzsolt, I. Quirt, R.G. Miller and R.A. Phillips, 1981. Stimulation of human NK cell activity by cultured cells. II Ingestion of aspirin by blood donors suppresses induced NK activity. Clin. Exp. Immunol., 44: 611-614.
    Direct Link  |  
  154. Porzsolt, F., S.F. Goldmann, W. Heit and H. Heimpel, 1979. Measurement of cell mediated cytotoxicity by post‐labeling surviving target cells. Tissue Antigens, 14: 398-406.
    CrossRef  |  Direct Link  |  
  155. Porzsolt, F., 1978. The Electrophoretic Mobility Test (EMT) and cancer diagnosis. Zeitschrift fur Immunitatsforschung: Immunobiology, 155: 183-187.
  156. Grohmann, P., W. Holmes, F. Porzsolt, I. Quirt, R.G. Miller and R.A. Phillips, 1978. Stimulation of human NK‐cell activity by cultured cells. I. Response of normals. Int. J. Cancer, 22: 528-534.
    CrossRef  |  Direct Link  |  
  157. Porzsolt, F., C. Tautz and W. Ax, 1975. Electrophoretic mobility test: I. Modifications to simplify the detection of malignant diseases in man. Behring Inst. Mitt., 57: 128-136.